{"id":"evolocumab-prefilled-syringe","safety":{"commonSideEffects":[{"rate":"2-3","effect":"Injection site reactions"},{"rate":"5-10","effect":"Nasopharyngitis"},{"rate":"5-10","effect":"Upper respiratory tract infection"},{"rate":"2-5","effect":"Influenza"},{"rate":"2-5","effect":"Back pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that degrades LDL receptors on hepatocytes. By binding to and inhibiting PCSK9, evolocumab prevents LDL receptor degradation, leading to increased expression of LDL receptors on liver cells and enhanced uptake of LDL cholesterol from the blood. This results in significant reductions in circulating LDL cholesterol levels.","oneSentence":"Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:53.633Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia (primary and secondary prevention of cardiovascular events)"},{"name":"Familial hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT03626831","phase":"PHASE4","title":"Effect of Evolocumab on Vascular Function","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2019-04-04","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":105},{"nctId":"NCT04573777","phase":"PHASE4","title":"Reducing Intracranial atheroSclErosis With Repatha","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2021-04-23","conditions":"Ischemic Stroke","enrollment":10},{"nctId":"NCT01849497","phase":"PHASE3","title":"Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-04-18","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":149}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Evolocumab Prefilled Syringe","genericName":"Evolocumab Prefilled Syringe","companyName":"University of Erlangen-Nürnberg Medical School","companyId":"university-of-erlangen-n-rnberg-medical-school","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream. Used for Hypercholesterolemia (primary and secondary prevention of cardiovascular events), Familial hypercholesterolemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}